Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

Mayne Pharma raises gross margin despite revenue decline in FY2026

Mayne Pharma reports FY2026 revenue fell to AUD 383.7m (-6%), while gross margin improved to 64.7% (+411 basis points). Adjusted EBITDA dropped 27% to AUD 34.2m, weighed down by higher sales and marketing costs, currency effects and litigation. The company highlights DistributeRx as a growth platform, reports around 5,000 new prescribing physicians and expects further margin improvement and fewer one-off items in FY2027. » More on de.investing.com
Mayne Pharma boosts margins despite stagnant revenue and high legal costs

Mayne Pharma reports largely flat revenue of A$212.1m for H1 FY26 while gross margin widened by 390 basis points to 65.3%. Adjusted EBITDA fell 8% to A$28.6m, weighed down by higher operating costs and exceptional legal costs of A$21.3m; operating cash flow dropped 38% to A$16.9m and cash holdings fell to A$67.3m. The dermatology segment saw a clear margin improvement from mix shift and direct sales, while the women’s health segment faced margin pressure despite volume growth. Management’s FY26 focus is on expanding the dermatology distribution strategy, monetising international investments and controlling legal costs to improve cash flow. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2023, Mayne Pharma Group has already paid €0.0179 in dividends. The last payout was in January 2023.

Financials

In the last quarter, Mayne Pharma Group had revenue of €103.93m and net profit of €23.87m

(EUR)	June 2026	YoY
Revenue	103.93m	-
Gross profit	50.62m	-
Net profit	23.87m	-
EBITDA	1.41m	-

Fundamentals

Metric	Value
Market capitalization	€169.4m
Number of shares	81.89m
52-week high/low	€3.73 - €1.26
Dividends	No
Beta	0.94
P/E ratio	10.81
PEG ratio	0.08
P/B ratio	0.70
P/S ratio	0.72

Company profile

Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, the United States, Asia, and internationally. The company operates through four segments: Generic Products, Specialty Products, Metrics Contract Services, and Mayne Pharma International. It provides oral drug delivery systems; and contract pharmaceutical development, manufacturing, and analytical services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.